| Company Name: |
Nanjing Shizhou Biology Technology Co.,Ltd
|
| Tel: |
17301488900 |
| Email: |
judy.xia@synzest.com |
| Products Intro: |
Product Name:rac-3’-O-Desethyl-3’-O-methyl Apremilast-d3
CAS:1258597-45-3
Purity:98% Package:1mg;5mg;10mg;100mg
|
| Company Name: |
Pharma Affiliates
|
| Tel: |
172-5066494 |
| Email: |
@pharmaffiliates.com |
| Products Intro: |
Product Name:Apremilast-d8
CAS:1258597-45-3
|
| Company Name: |
SynZeal Research Pvt Ltd
|
| Tel: |
+1 226-802-2078 |
| Email: |
standards@synzeal.com |
| Products Intro: |
Product Name:Apremilast-d8
CAS:1258597-45-3
|
|
| | Apremilast-d8 Basic information |
| | Apremilast-d8 Chemical Properties |
| | Apremilast-d8 Usage And Synthesis |
| Uses | Apremilast-d8 (CC-10004-d8) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1][2]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015 Sep 15;17:249. DOI:10.1186/s13075-015-0771-6
[3] Chen LG, et al. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. J Chromatogr Sci. 2016 Sep;54(8):1336-40. DOI:10.1093/chromsci/bmw072 |
| | Apremilast-d8 Preparation Products And Raw materials |
|